{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:58:16Z","timestamp":1791979096001,"version":"4.4.0"},"reference-count":34,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T00:00:00Z","timestamp":1574985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Daptomycin, a lipopeptide antibiotic, is one of the therapeutic options used for the treatment of vancomycin-resistant enterococci (VRE). Recently, the Clinical and Laboratory Standards Institute (CLSI) M100 30th edition has removed the susceptibility (S) breakpoint for Enterococcus faecium and replaced it with a susceptible dose-dependent (SDD) breakpoint of \u22644 \u03bcg\/mL, with a suggested dosage of 8\u201312 mg\/kg\/day. Herein, we aimed to determine the minimum inhibitory concentration (MIC) values of daptomycin against clinical VRE isolates and to study the appropriate daptomycin dosing regimens among critically ill patients based on the new susceptibility CLSI breakpoint. The MIC determination of daptomycin was performed using E-test strips among clinical VRE strains isolated from patients at the Phramongkutklao Hospital. We used Monte Carlo simulation to calculate the probability of target attainment (PTA) and the cumulative fraction of response (CFR) of the ratio of the free area under the curve to MIC (fAUC0\u201324\/MIC) &gt; 27.4 and fAUC0\u201324\/MIC &gt; 20 for survival and microbiological response, respectively, at the first day and steady state. Further, we determined that the simulated daptomycin dosing regimen met the minimum concentration (Cmin) requirements for safety of being below 24.3 mg\/L. All of the 48 VRE isolates were E. faecium strains, and the percentiles at the 50th and 90th MIC of daptomycin were 1 and 1.5 \u03bcg\/mL, respectively. At MIC \u2264 2 \u03bcg\/mL, a daptomycin dosage of 12 mg\/kg\/day achieved the PTA target of survival and microbiological response at the first 24 h time point and steady state. For a MIC of 4 \u03bcg\/mL, none of the dosage regimens achieved the PTA target. For CFR, a dosage of 8\u201312 mg\/kg\/day could achieve the 90% CFR target at the first day and steady state. All dosing regimens had a low probability of Cmin being greater than 24.3 mg\/L. In conclusion, the MIC of VRE against daptomycin is quite low, and loading and maintenance doses with 8 mg\/kg\/day were determined to be optimal and safe.<\/jats:p>","DOI":"10.3390\/antibiotics8040245","type":"journal-article","created":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T10:58:21Z","timestamp":1575025101000},"page":"245","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Optimizing the Dosing Regimens of Daptomycin Based on the Susceptible Dose-Dependent Breakpoint against Vancomycin-Resistant Enterococci Infection"],"prefix":"10.3390","volume":"8","author":[{"given":"Wichai","family":"Santimaleeworagun","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Faculty of Pharmacy, Silpakorn University, Nakorn Pathom 73000, Thailand"},{"name":"Pharmaceutical Initiative for Resistant Bacteria and Infectious Diseases Working Group (PIRBIG), Nakorn Pathom 73000, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7939-6834","authenticated-orcid":false,"given":"Dhitiwat","family":"Changpradub","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease, Department of Medicine, Phramongkutklao Hospital, Bangkok 10400, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudaluck","family":"Thunyaharn","sequence":"additional","affiliation":[{"name":"Faculty of Medical Technology, Nakhonratchasima College, Nakhon Ratchasima 30000, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5265-5808","authenticated-orcid":false,"given":"Jatapat","family":"Hemapanpairoa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Pharmaceutical Care, Faculty of Pharmaceutical Sciences, Burapha University, Chonburi 20131, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,11,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.2147\/IDR.S208298","article-title":"Vancomycin-resistant enterococcal infection in a Thai university hospital: Clinical characteristics, treatment outcomes, and synergistic effect","volume":"12","author":"Hemapanpairoa","year":"2019","journal-title":"Infect. Drug Resist."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1017\/ice.2016.254","article-title":"Incidence and Outcomes Associated with Infections Caused by Vancomycin-Resistant Enterococci in the United States: Systematic Literature Review and Meta-Analysis","volume":"38","author":"Chiang","year":"2017","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_3","unstructured":"National Antimicrobial Resistance Surveillance Center (2019, September 09). Thailand, Available online: http:\/\/narst.dmsc.moph.go.th\/."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","article-title":"Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications","volume":"132","author":"Barsic","year":"2015","journal-title":"Circulation"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/599376","article-title":"Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America","volume":"49","author":"Mermel","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1093\/cid\/ciu296","article-title":"Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1093\/cid\/civ482","article-title":"2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adultsa","volume":"61","author":"Berbari","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Waller, D.G., and Sampson, A.P. (2018). 51\u2014Chemotherapy of infections. Medical Pharmacology and Therapeutics, Elsevier. [5th ed.].","DOI":"10.1016\/B978-0-7020-7167-6.00051-8"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"American Thoracic Society and Infectious Diseases Society of America (2005). Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia. Am. J. Respir. Crit. Care Med., 171, 388\u2013416.","DOI":"10.1164\/rccm.200405-644ST"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/jac\/dky072","article-title":"Association of daptomycin dosing regimen and mortality in patients with VRE bacteraemia: A review","volume":"73","author":"Foolad","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/cid\/cix024","article-title":"Effect of Daptomycin Dose on the Outcome of Vancomycin-Resistant, Daptomycin-Susceptible Enterococcus faecium Bacteremia","volume":"64","author":"Chuang","year":"2017","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_12","first-page":"605","article-title":"Comparative Effectiveness and Safety of Standard-, Medium-, and High-Dose Daptomycin Strategies for the Treatment of Vancomycin-Resistant Enterococcal Bacteremia among Veterans Affairs Patients","volume":"64","author":"Britt","year":"2017","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e00600","DOI":"10.1128\/JCM.00600-19","article-title":"The New, New Daptomycin Breakpoint for Enterococcus spp.","volume":"57","author":"Humphries","year":"2019","journal-title":"J. Clin. Microbiol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Satlin, M.J., Nicolau, D.P., Humphries, R.M., Kuti, J.L., Campeau, S.A., Lewis, J.S., Weinstein, M.P., Jorgensen, J.H., and Clinical and Laboratory Standards Institute Subcommittee on Antimicrobial Susceptibility Testing and Ad Hoc Working Group on Revision of Daptomycin Enterococcal Breakpoints (2019). Development of Daptomycin Susceptibility Breakpoints for Enterococcus faecium and Revision of the Breakpoints for other Enterococcal species by the Clinical and Laboratory Standards Institute. Clin. Infect. Dis.","DOI":"10.1093\/cid\/ciz845"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1128\/AAC.48.1.63-68.2004","article-title":"In vivo pharmacodynamic activity of daptomycin","volume":"48","author":"Safdar","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1093\/cid\/ciy749","article-title":"Pharmacodynamic Analysis of Daptomycin-treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint","volume":"68","author":"Avery","year":"2019","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1086\/652767","article-title":"Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: Data from a randomized trial of patients with bacteremia and endocarditis","volume":"50","author":"Bhavnani","year":"2010","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ccc.2006.02.011","article-title":"Pharmacokinetic Changes in Critical Illness","volume":"22","author":"Boucher","year":"2006","journal-title":"Crit. Care Clin."},{"key":"ref_19","first-page":"5","article-title":"Plasma pharmacokinetics of antimicrobial agents in critically ill patients","volume":"8","author":"Pea","year":"2013","journal-title":"Curr. Clin. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","article-title":"Individualised antibiotic dosing for patients who are critically ill: Challenges and potential solutions","volume":"14","author":"Roberts","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2147\/IDR.S54125","article-title":"Vancomycin-resistant enterococcal infections: Epidemiology, clinical manifestations, and optimal management","volume":"8","author":"Crank","year":"2015","journal-title":"Infect. Drug Resist."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/jac\/dkh143","article-title":"Daptomycin activity and spectrum: A worldwide sample of 6737 clinical Gram-positive organisms","volume":"53","author":"Streit","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/jac\/dkq087","article-title":"A potential role for daptomycin in enterococcal infections: What is the evidence?","volume":"65","author":"Chaves","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1086\/504084","article-title":"An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus","volume":"42","author":"Patel","year":"2006","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2217\/fmb-2016-0140","article-title":"Optimization of linezolid treatment regimens for Gram-positive bacterial infections based on pharmacokinetic\/pharmacodynamic analysis","volume":"12","author":"Yang","year":"2017","journal-title":"Future Microbiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1128\/CMR.00030-13","article-title":"A current perspective on daptomycin for the clinical microbiologist","volume":"26","author":"Humphries","year":"2013","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1093\/cid\/ciw173","article-title":"Influence of Minimum Inhibitory Concentration in Clinical Outcomes of Enterococcus faecium Bacteremia Treated with Daptomycin: Is it Time to Change the Breakpoint?","volume":"62","author":"Shukla","year":"2016","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e00506","DOI":"10.1128\/AAC.00506-18","article-title":"Pharmacodynamics of Daptomycin against Enterococcus faecium and Enterococcus faecalis in the murine thigh infection model","volume":"62","author":"Kidd","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/cid\/cit582","article-title":"Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia","volume":"57","author":"Falcone","year":"2013","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1128\/AAC.00943-08","article-title":"Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever","volume":"53","author":"Bubalo","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ijantimicag.2018.03.008","article-title":"Population pharmacokinetics of daptomycin in critically ill patients","volume":"52","author":"Soraluce","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Kebriaei, R., Rice, S.A., Singh, K.V., Stamper, K.C., Dinh, A.Q., Rios, R., Diaz, L., Murray, B.E., Munita, J.M., and Tran, T.T. (2018). Influence of Inoculum Effect on the Efficacy of Daptomycin Monotherapy and in Combination with beta-Lactams against Daptomycin-Susceptible Enterococcus faecium Harboring LiaSR Substitutions. Antimicrob. Agents Chemother., 62.","DOI":"10.1128\/AAC.00315-18"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1093\/jac\/dkv007","article-title":"beta-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium","volume":"70","author":"Smith","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_34","first-page":"286","article-title":"Dose-independent daptomycin associated rhabdomyolysis: Case report","volume":"9","author":"Metwali","year":"2018","journal-title":"J. Basic Clin. Pharm."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/8\/4\/245\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:38:44Z","timestamp":1760189924000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/8\/4\/245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,29]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["antibiotics8040245"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics8040245","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,29]]}}}